Spike Protein News and Research

RSS

Greater cross-neutralization against UK SARS-CoV-2 variant in vaccinated individuals with prior infection

A team of researchers in Spain has observed that, of those who have been vaccinated against SARS-CoV-2, higher titers of neutralizing antibodies for the B.1.1.7 variant (originating in the UK) were present in those who had previously been infected with the virus.

9 Mar 2021

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Scientists from the United States has recently evaluated the safety and efficacy profiles of ultraviolet-A (UVA) light applied via an endotracheal tube to critically ill COVID-19 patients.

9 Mar 2021

Study suggests sewer rats immune to SARS-CoV-2

Although the researchers found that the rats tested negative for the virus, they say it is important to continue monitoring animals for the virus as it mutates, making previously resistant species susceptible to infection.

8 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.

8 Mar 2021

Worse problems with SARS-CoV-2 variants may be on the way

Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.

8 Mar 2021

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

A new paper in the journal Life presents an early review of the viral factors involved in initiating and effecting apoptosis within infected cells.

8 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

A recent study reports the safety and high efficacy of an adjuvanted vaccine candidate against SARS-CoV-2 and the complications of COVID-19.

5 Mar 2021

New COVID-19 variants can evade antibodies that work against original form of the virus

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic.

5 Mar 2021

SARS-CoV-2 can evade immune response by T-killer cells through mutations

The body's immune response plays a crucial role in the course of a SARS-CoV-2 infection. In addition to antibodies, the so-called T-killer cells, are also responsible for detecting viruses in the body and eliminating them.

5 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers found a small molecule that inhibits different virus proteins and significantly reduces infection in cells. Combined with the antiviral remdesivir, its potency increases significantly, suggesting it may be a potential antiviral candidate for the treatment of COVID-19.

4 Mar 2021

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

The currently approved mRNA vaccines from Moderna and Pfizer-BioNTech help create neutralizing antibodies against the SARS-CoV-2 spike protein. Both companies designed their vaccines to be delivered in two doses. However, given the limited supply of vaccines worldwide, a new modeling study has suggested that vaccinating more people with the first dose and delaying the second could be an alternate route to achieving population immunity that could reduce mortality rates.

4 Mar 2021

Multiple COVID-19 variants of concern have reached Houston, Texas

New research by a team at Houston Methodist Hospital in the United States has modeled the aggressive genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) observed in the United Kingdom to document viral community spread in Houston, Texas.

4 Mar 2021

Spike Protein News and Research

Greater cross-neutralization against UK SARS-CoV-2 variant in vaccinated individuals with prior infection

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Study suggests sewer rats immune to SARS-CoV-2

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Worse problems with SARS-CoV-2 variants may be on the way

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers present fragment-based computational design of antibodies that target structured epitopes

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

New COVID-19 variants can evade antibodies that work against original form of the virus

SARS-CoV-2 can evade immune response by T-killer cells through mutations

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

Multiple COVID-19 variants of concern have reached Houston, Texas

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News